{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T18:33:19Z","timestamp":1771266799972,"version":"3.50.1"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:00:00Z","timestamp":1705104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:00:00Z","timestamp":1705104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NIH\/NCATS","award":["KL2TR002552"],"award-info":[{"award-number":["KL2TR002552"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s11882-024-01125-1","type":"journal-article","created":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T09:02:51Z","timestamp":1705136571000},"page":"73-80","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Mast Cells in Aspirin-Exacerbated Respiratory Disease"],"prefix":"10.1007","volume":"24","author":[{"given":"Edsel M.","family":"Abud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew A.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,13]]},"reference":[{"key":"1125_CR1","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.immuni.2018.09.023","volume":"49","author":"Z Li","year":"2018","unstructured":"Li Z, et al. Adult connective tissue-resident mast cells originate from late erythro-myeloid progenitors. Immunity. 2018;49:640-653 e645.","journal-title":"Immunity"},{"key":"1125_CR2","doi-asserted-by":"crossref","unstructured":"Tauber M, et al.\u00a0Landscape of mast cell populations across organs in mice and humans. J Exp Med. 2023;220.","DOI":"10.1084\/jem.20230570"},{"key":"1125_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41577-022-00731-2","volume":"23","author":"AL St John","year":"2023","unstructured":"St John AL, Rathore APS, Ginhoux F. New perspectives on the origins and heterogeneity of mast cells. Nat Rev Immunol. 2023;23:55\u201368.","journal-title":"Nat Rev Immunol"},{"key":"1125_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jdermsci.2007.09.009","volume":"49","author":"SJ Galli","year":"2008","unstructured":"Galli SJ, Tsai M. Mast cells: versatile regulators of inflammation, tissue remodeling, host defense and homeostasis. J Dermatol Sci. 2008;49:7\u201319.","journal-title":"J Dermatol Sci"},{"key":"1125_CR5","doi-asserted-by":"publisher","first-page":"1213320","DOI":"10.3389\/fmed.2023.1213320","volume":"10","author":"KN Dileepan","year":"2023","unstructured":"Dileepan KN, et al. Mast cell-mediated immune regulation in health and disease. Front Med (Lausanne). 2023;10:1213320.","journal-title":"Front Med (Lausanne)"},{"key":"1125_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002619","volume":"8","author":"M Urb","year":"2012","unstructured":"Urb M, Sheppard DC. The role of mast cells in the defence against pathogens. PLoS Pathog. 2012;8: e1002619.","journal-title":"PLoS Pathog"},{"key":"1125_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/imr.12634","volume":"282","author":"K Mukai","year":"2018","unstructured":"Mukai K, Tsai M, Saito H, Galli SJ. Mast cells as sources of cytokines, chemokines, and growth factors. Immunol Rev. 2018;282:121\u201350.","journal-title":"Immunol Rev"},{"key":"1125_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.it.2017.10.005","volume":"39","author":"F Siebenhaar","year":"2018","unstructured":"Siebenhaar F, Redegeld FA, Bischoff SC, Gibbs BF, Maurer M. mast cells as drivers of disease and therapeutic targets. Trends Immunol. 2018;39:151\u201362.","journal-title":"Trends Immunol"},{"key":"1125_CR9","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.cell.2010.03.004","volume":"140","author":"RM Locksley","year":"2010","unstructured":"Locksley RM. Asthma and allergic inflammation. Cell. 2010;140:777\u201383.","journal-title":"Cell"},{"key":"1125_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/imr.12627","volume":"282","author":"G Varricchi","year":"2018","unstructured":"Varricchi G, Raap U, Rivellese F, Marone G, Gibbs BF. Human mast cells and basophils-how are they similar how are they different? Immunol Rev. 2018;282:8\u201334.","journal-title":"Immunol Rev"},{"key":"1125_CR11","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s12016-019-08769-2","volume":"58","author":"D Elieh Ali Komi","year":"2020","unstructured":"Elieh Ali Komi D, Wohrl S, Bielory L. Mast cell biology at molecular level: a comprehensive review. Clin Rev Allergy Immunol. 2020;58:342\u201365.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1125_CR12","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3389\/fimmu.2014.00453","volume":"5","author":"U Blank","year":"2014","unstructured":"Blank U, et al. Vesicular trafficking and signaling for cytokine and chemokine secretion in mast cells. Front Immunol. 2014;5:453.","journal-title":"Front Immunol"},{"key":"1125_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4049\/jimmunol.1301753","volume":"193","author":"JW Steinke","year":"2014","unstructured":"Steinke JW, Negri J, Liu L, Payne SC, Borish L. Aspirin activation of eosinophils and mast cells: implications in the pathogenesis of aspirin-exacerbated respiratory disease. J Immunol. 2014;193:41\u20137.","journal-title":"J Immunol"},{"key":"1125_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev-immunol-071719-094903","volume":"38","author":"SJ Galli","year":"2020","unstructured":"Galli SJ, Gaudenzio N, Tsai M. Mast cells in inflammation and disease: recent progress and ongoing concerns. Annu Rev Immunol. 2020;38:49\u201377.","journal-title":"Annu Rev Immunol"},{"key":"1125_CR15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s12016-018-8720-1","volume":"56","author":"D Elieh Ali Komi","year":"2019","unstructured":"Elieh Ali Komi D, Bjermer L. Mast cell-mediated orchestration of the immune responses in human allergic asthma: current insights. Clin Rev Allergy Immunol. 2019;56:234\u201347.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1125_CR16","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jaci.2019.02.027","volume":"144","author":"EM Gordon","year":"2019","unstructured":"Gordon EM, et al. Apolipoprotein E is a concentration-dependent pulmonary danger signal that activates the NLRP3 inflammasome and IL-1beta secretion by bronchoalveolar fluid macrophages from asthmatic subjects. J Allergy Clin Immunol. 2019;144:426-441 e423.","journal-title":"J Allergy Clin Immunol"},{"key":"1125_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/imr.12636","volume":"282","author":"B Frossi","year":"2018","unstructured":"Frossi B, Mion F, Sibilano R, Danelli L, Pucillo CEM. Is it time for a new classification of mast cells? What do we know about mast cell heterogeneity? Immunol Rev. 2018;282:35\u201346.","journal-title":"Immunol Rev"},{"key":"1125_CR18","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jaci.2022.02.016","volume":"149","author":"A Kato","year":"2022","unstructured":"\u2022\u2022 Kato A, Schleimer RP, Bleier BS. Mechanisms and pathogenesis of chronic rhinosinusitis. J Allergy Clin Immunol. 2022;149:1491\u2013503. This review article is an excellent resource on the known mechanism and pathogenesis of CRS.","journal-title":"J Allergy Clin Immunol"},{"key":"1125_CR19","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/all.15074","volume":"77","author":"A Kato","year":"2022","unstructured":"Kato A, et al. Endotypes of chronic rhinosinusitis: relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches. Allergy. 2022;77:812\u201326.","journal-title":"Allergy"},{"key":"1125_CR20","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1111\/all.13875","volume":"74","author":"WJ Fokkens","year":"2019","unstructured":"Fokkens WJ, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74:2312\u20139.","journal-title":"Allergy"},{"key":"1125_CR21","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1016\/j.jaci.2009.11.017","volume":"125","author":"KD Stone","year":"2010","unstructured":"Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol. 2010;125:S73-80.","journal-title":"J Allergy Clin Immunol"},{"key":"1125_CR22","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.jaci.2012.02.046","volume":"130","author":"T Takabayashi","year":"2012","unstructured":"Takabayashi T, et al. Glandular mast cells with distinct phenotype are highly elevated in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2012;130:410-420 e415.","journal-title":"J Allergy Clin Immunol"},{"key":"1125_CR23","doi-asserted-by":"publisher","first-page":"12101","DOI":"10.1038\/s41598-023-39149-8","volume":"13","author":"M Gelardi","year":"2023","unstructured":"Gelardi M, et al. Eosinophil-mast cell pattern of intraepithelial infiltration as a marker of severity in CRSwNP. Sci Rep. 2023;13:12101.","journal-title":"Sci Rep"},{"key":"1125_CR24","first-page":"162","volume":"43","author":"N Zhang","year":"2005","unstructured":"Zhang N, et al. An update on the impact of Staphylococcus aureus enterotoxins in chronic sinusitis with nasal polyposis. Rhinology. 2005;43:162\u20138.","journal-title":"Rhinology"},{"key":"1125_CR25","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","volume":"146","author":"P Gevaert","year":"2020","unstructured":"Gevaert P, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146:595\u2013605.","journal-title":"J Allergy Clin Immunol"},{"key":"1125_CR26","doi-asserted-by":"publisher","first-page":"655","DOI":"10.2217\/imt-2021-0310","volume":"14","author":"MJ Lelegren","year":"2022","unstructured":"Lelegren MJ, Son SY, Han JK, Lam KK. A review of phase III clinical trials of US FDA-approved biologic therapies for chronic rhinosinusitis with nasal polyposis. Immunotherapy. 2022;14:655\u201362.","journal-title":"Immunotherapy"},{"key":"1125_CR27","doi-asserted-by":"crossref","unstructured":"Dwyer DF,\u00a0et al.\u00a0Human airway mast cells proliferate and acquire distinct inflammation-driven phenotypes during type 2 inflammation. Sci Immunol. 2021;6.","DOI":"10.1126\/sciimmunol.abb7221"},{"key":"1125_CR28","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/S0140-6736(22)02125-0","volume":"401","author":"C Porsbjerg","year":"2023","unstructured":"Porsbjerg C, Melen E, Lehtimaki L, Shaw D. Asthma. Lancet. 2023;401:858\u201373.","journal-title":"Lancet"},{"key":"1125_CR29","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.anai.2018.07.029","volume":"121","author":"TF Carr","year":"2018","unstructured":"Carr TF, Kraft M. Use of biomarkers to identify phenotypes and endotypes of severeasthma. Ann Allergy Asthma Immunol. 2018;121:414\u201320.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1125_CR30","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41577-021-00622-y","volume":"22","author":"P Kolkhir","year":"2022","unstructured":"Kolkhir P, Elieh-Ali-Komi D, Metz M, Siebenhaar F, Maurer M. Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases. Nat Rev Immunol. 2022;22:294\u2013308.","journal-title":"Nat Rev Immunol"},{"key":"1125_CR31","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1164\/ajrccm\/148.1.80","volume":"148","author":"PG Gibson","year":"1993","unstructured":"Gibson PG, et al. Intraepithelial mast cells in allergic and nonallergic asthma. Assessment using bronchial brushings. Am Rev Respir Dis. 1993;148:80\u20136.","journal-title":"Am Rev Respir Dis"},{"key":"1125_CR32","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/0091-6749(92)90462-B","volume":"90","author":"S Juliusson","year":"1992","unstructured":"Juliusson S, Pipkorn U, Karlsson G, Enerback L. Mast cells and eosinophils in the allergic mucosal response to allergen challenge: changes in distribution and signs of activation in relation to symptoms. J Allergy Clin Immunol. 1992;90:898\u2013909.","journal-title":"J Allergy Clin Immunol"},{"key":"1125_CR33","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/ni.3445","volume":"17","author":"DF Dwyer","year":"2016","unstructured":"Dwyer DF, Barrett NA, Austen KF. C. Immunological genome project, expression profiling of constitutive mast cells reveals a unique identity within the immune system. Nat Immunol. 2016;17:878\u201387.","journal-title":"Nat Immunol"},{"key":"1125_CR34","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1016\/j.jaci.2022.02.025","volume":"149","author":"N Ben-Baruch Morgenstern","year":"2022","unstructured":"Ben-Baruch Morgenstern N, et al. Single-cell RNA sequencing of mast cells in eosinophilic esophagitis reveals heterogeneity, local proliferation, and activation that persists in remission. J Allergy Clin Immunol. 2022;149:2062\u201377.","journal-title":"J Allergy Clin Immunol"},{"key":"1125_CR35","doi-asserted-by":"publisher","first-page":"685","DOI":"10.2174\/138161211795428975","volume":"17","author":"RJ Carter","year":"2011","unstructured":"Carter RJ, Bradding P. The role of mast cells in the structural alterations of the airways as a potential mechanism in the pathogenesis of severe asthma. Curr Pharm Des. 2011;17:685\u201398.","journal-title":"Curr Pharm Des"},{"key":"1125_CR36","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1165\/rcmb.2016-0307TR","volume":"56","author":"CA Ojiaku","year":"2017","unstructured":"Ojiaku CA, Yoo EJ, Panettieri RA Jr. Transforming growth factor beta1 function in airway remodeling and hyperresponsiveness. The Missing Link? Am J Respir Cell Mol Biol. 2017;56:432\u201342.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"1125_CR37","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1183\/09031936.00068712","volume":"43","author":"R Firszt","year":"2014","unstructured":"Firszt R, et al. Interleukin-13 induces collagen type-1 expression through matrix metalloproteinase-2 and transforming growth factor-beta1 in airway fibroblasts in asthma. Eur Respir J. 2014;43:464\u201373.","journal-title":"Eur Respir J"},{"key":"1125_CR38","doi-asserted-by":"publisher","first-page":"L193","DOI":"10.1152\/ajplung.2000.278.1.L193","volume":"278","author":"IA Akers","year":"2000","unstructured":"Akers IA, et al. Mast cell tryptase stimulates human lung fibroblast proliferation via protease-activated receptor-2. Am J Physiol Lung Cell Mol Physiol. 2000;278:L193-201.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"1125_CR39","doi-asserted-by":"crossref","unstructured":"Pejler G. The emerging role of mast cell proteases in asthma. Eur Respir J. 2019;54.","DOI":"10.1183\/13993003.00685-2019"},{"key":"1125_CR40","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1164\/rccm.202102-0355OC","volume":"205","author":"A Tiotiu","year":"2022","unstructured":"Tiotiu A, et al. Association of differential mast cell activation with granulocytic inflammation in severe asthma. Am J Respir Crit Care Med. 2022;205:397\u2013411.","journal-title":"Am J Respir Crit Care Med"},{"key":"1125_CR41","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1183\/13993003.01098-2015","volume":"47","author":"G Wang","year":"2016","unstructured":"Wang G, et al. Sputum mast cell subtypes relate to eosinophilia and corticosteroid response in asthma. Eur Respir J. 2016;47:1123\u201333.","journal-title":"Eur Respir J"},{"key":"1125_CR42","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1164\/rccm.201002-0295OC","volume":"183","author":"S Balzar","year":"2011","unstructured":"Balzar S, et al. Mast cell phenotype, location, and activation in severe asthma. Data from the Severe Asthma Research Program. Am J Respir Crit Care Med. 2011;183:299\u2013309.","journal-title":"Am J Respir Crit Care Med"},{"key":"1125_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.924244","volume":"13","author":"P Siddhuraj","year":"2022","unstructured":"Siddhuraj P, et al. Dynamically upregulated mast cell CPA3 patterns in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Front Immunol. 2022;13: 924244.","journal-title":"Front Immunol"},{"key":"1125_CR44","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s12016-018-8670-7","volume":"55","author":"SR Durrani","year":"2018","unstructured":"Durrani SR, Mukkada VA, Guilbert TW. Eosinophilic esophagitis: an important comorbid condition of asthma? Clin Rev Allergy Immunol. 2018;55:56\u201364.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1125_CR45","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.anai.2017.02.006","volume":"118","author":"J Gonzalez-Cervera","year":"2017","unstructured":"Gonzalez-Cervera J, et al. Association between atopic manifestations and eosinophilic esophagitis: a systematic review and meta-analysis. Ann Allergy Asthma Immunol. 2017;118:582-590 e582.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1125_CR46","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41577-020-0285-6","volume":"20","author":"MG Netea","year":"2020","unstructured":"Netea MG, et al. Defining trained immunity and its role in health and disease. Nat Rev Immunol. 2020;20:375\u201388.","journal-title":"Nat Rev Immunol"},{"key":"1125_CR47","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.jaci.2019.08.022","volume":"144","author":"JA Boyce","year":"2019","unstructured":"Boyce JA. Aspirin sensitivity: lessons in the regulation (and dysregulation) of mast cell function. J Allergy Clin Immunol. 2019;144:875\u201381.","journal-title":"J Allergy Clin Immunol"},{"key":"1125_CR48","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1164\/ajrccm\/137.4.847","volume":"137","author":"NR Ferreri","year":"1988","unstructured":"Ferreri NR, Howland WC, Stevenson DD, Spiegelberg HL. Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin. Am Rev Respir Dis. 1988;137:847\u201354.","journal-title":"Am Rev Respir Dis"},{"key":"1125_CR49","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1159\/000024002","volume":"117","author":"S Yoshida","year":"1998","unstructured":"Yoshida S, et al. Bronchial hyperresponsiveness, hypersensitivity to analgesics and urinary leukotriene E4 excretion in patients with aspirin-intolerant asthma. Int Arch Allergy Immunol. 1998;117:146\u201351.","journal-title":"Int Arch Allergy Immunol"},{"key":"1125_CR50","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1183\/09031936.93.06030391","volume":"6","author":"K Sladek","year":"1993","unstructured":"Sladek K, Szczeklik A. Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma. Eur Respir J. 1993;6:391\u20139.","journal-title":"Eur Respir J"},{"key":"1125_CR51","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jaci.2014.07.031","volume":"135","author":"KN Cahill","year":"2015","unstructured":"Cahill KN, Bensko JC, Boyce JA, Laidlaw TM. Prostaglandin D(2): a dominant mediator of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2015;135:245\u201352.","journal-title":"J Allergy Clin Immunol"},{"key":"1125_CR52","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1164\/rccm.201904-0716ED","volume":"200","author":"L Borish","year":"2019","unstructured":"Borish L. Aspirin-exacerbated respiratory disease: a syndrome of mast cell-mediated PgD2 overproduction. Am J Respir Crit Care Med. 2019;200:651\u20132.","journal-title":"Am J Respir Crit Care Med"},{"key":"1125_CR53","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.jaci.2018.10.007","volume":"143","author":"KN Cahill","year":"2019","unstructured":"Cahill KN, et al. Plasma tryptase elevation during aspirin-induced reactions in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2019;143:799-803 e792.","journal-title":"J Allergy Clin Immunol"},{"key":"1125_CR54","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1164\/ajrccm.153.1.8542168","volume":"153","author":"SM Nasser","year":"1996","unstructured":"Nasser SM, et al. Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects. Am J Respir Crit Care Med. 1996;153:90\u20136.","journal-title":"Am J Respir Crit Care Med"},{"key":"1125_CR55","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1136\/thx.51.1.64","volume":"51","author":"S Nasser","year":"1996","unstructured":"Nasser S, et al. Effect of endobronchial aspirin challenge on inflammatory cells in bronchial biopsy samples from aspirin-sensitive asthmatic subjects. Thorax. 1996;51:64\u201370.","journal-title":"Thorax"},{"key":"1125_CR56","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1172\/JCI620","volume":"101","author":"AS Cowburn","year":"1998","unstructured":"Cowburn AS, et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest. 1998;101:834\u201346.","journal-title":"J Clin Invest"},{"key":"1125_CR57","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1056\/NEJMoa013508","volume":"347","author":"AR Sousa","year":"2002","unstructured":"Sousa AR, Parikh A, Scadding G, Corrigan CJ, Lee TH. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med. 2002;347:1493\u20139.","journal-title":"N Engl J Med"},{"key":"1125_CR58","first-page":"1515","volume":"41","author":"S Imokawa","year":"1992","unstructured":"Imokawa S, et al. Sodium cromoglycate nebulized solution has an acute bronchodilative effect in patients with aspirin-intolerant asthma (AIA). Arerugi. 1992;41:1515\u201320.","journal-title":"Arerugi"},{"key":"1125_CR59","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1111\/j.1365-2222.2004.02034.x","volume":"34","author":"H Mita","year":"2004","unstructured":"Mita H, Higashi N, Taniguchi M, Higashi A, Akiyama K. Increase in urinary leukotriene B4 glucuronide concentration in patients with aspirin-intolerant asthma after intravenous aspirin challenge. Clin Exp Allergy. 2004;34:1262\u20139.","journal-title":"Clin Exp Allergy"},{"key":"1125_CR60","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s11882-022-01049-8","volume":"22","author":"M Marquette","year":"2022","unstructured":"Marquette M, et al. Urinary leukotriene E4 as a biomarker in NSAID-exacerbated respiratory disease (N-ERD): a systematic review and meta-analysis. Curr Allergy Asthma Rep. 2022;22:209\u201329.","journal-title":"Curr Allergy Asthma Rep"},{"key":"1125_CR61","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S1081-1206(10)62575-6","volume":"85","author":"DD Stevenson","year":"2000","unstructured":"Stevenson DD, Simon RA, Mathison DA, Christiansen SC. Montelukast is only partially effective in inhibiting aspirin responses in aspirin-sensitive asthmatics. Ann Allergy Asthma Immunol. 2000;85:477\u201382.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1125_CR62","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1046\/j.1398-9995.2003.00351.x","volume":"59","author":"C Micheletto","year":"2004","unstructured":"Micheletto C, et al. Montelukast 10 mg improves nasal function and nasal response to aspirin in ASA-sensitive asthmatics: a controlled study vs placebo. Allergy. 2004;59:289\u201394.","journal-title":"Allergy"},{"key":"1125_CR63","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1164\/ajrccm.165.1.2010080","volume":"165","author":"SE Dahlen","year":"2002","unstructured":"Dahlen SE, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165:9\u201314.","journal-title":"Am J Respir Crit Care Med"},{"key":"1125_CR64","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jaci.2020.10.043","volume":"147","author":"WW Stevens","year":"2021","unstructured":"Stevens WW, et al. The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A work group report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2021;147:827\u201344.","journal-title":"J Allergy Clin Immunol"},{"key":"1125_CR65","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2332\/allergolint.O-08-545","volume":"57","author":"T Yoshimura","year":"2008","unstructured":"Yoshimura T, Yoshikawa M, Otori N, Haruna S, Moriyama H. Correlation between the prostaglandin D(2)\/E(2) ratio in nasal polyps and the recalcitrant pathophysiology of chronic rhinosinusitis associated with bronchial asthma. Allergol Int. 2008;57:429\u201336.","journal-title":"Allergol Int"},{"key":"1125_CR66","doi-asserted-by":"publisher","first-page":"186","DOI":"10.4168\/aair.2011.3.3.186","volume":"3","author":"S Kimura","year":"2011","unstructured":"Kimura S, et al. Increased expression and role of thymic stromal lymphopoietin in nasal polyposis. Allergy Asthma Immunol Res. 2011;3:186\u201393.","journal-title":"Allergy Asthma Immunol Res"},{"key":"1125_CR67","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/j.jaci.2015.10.020","volume":"137","author":"KM Buchheit","year":"2016","unstructured":"Buchheit KM, et al. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016;137:1566-1576 e1565.","journal-title":"J Allergy Clin Immunol"},{"key":"1125_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2015.96","volume":"48","author":"SK Kong","year":"2016","unstructured":"Kong SK, et al. Aspirin induces IL-4 production: augmented IL-4 production in aspirin-exacerbated respiratory disease. Exp Mol Med. 2016;48: e202.","journal-title":"Exp Mol Med"},{"key":"1125_CR69","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.jaci.2018.06.033","volume":"143","author":"D Pan","year":"2019","unstructured":"Pan D, et al. COX-1 mediates IL-33-induced extracellular signal-regulated kinase activation in mast cells: implications for aspirin sensitivity. J Allergy Clin Immunol. 2019;143:1047-1057 e1048.","journal-title":"J Allergy Clin Immunol"},{"key":"1125_CR70","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/j.jaci.2017.09.050","volume":"141","author":"J Maric","year":"2018","unstructured":"Maric J, et al. Prostaglandin E(2) suppresses human group 2 innate lymphoid cell function. J Allergy Clin Immunol. 2018;141:1761-1773 e1766.","journal-title":"J Allergy Clin Immunol"},{"key":"1125_CR71","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.4049\/jimmunol.169.7.3963","volume":"169","author":"JG Martin","year":"2002","unstructured":"Martin JG, et al. The immunomodulatory actions of prostaglandin E2 on allergic airway responses in the rat. J Immunol. 2002;169:3963\u20139.","journal-title":"J Immunol"},{"key":"1125_CR72","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1164\/ajrccm.153.2.8564100","volume":"153","author":"P Sestini","year":"1996","unstructured":"Sestini P, et al. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med. 1996;153:572\u20135.","journal-title":"Am J Respir Crit Care Med"},{"key":"1125_CR73","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","volume":"9","author":"TM Laidlaw","year":"2021","unstructured":"Laidlaw TM, Mullol J, Woessner KM, Amin N, Mannent LP. Chronic rhinosinusitis with nasal polyps and asthma. J Allergy Clin Immunol Pract. 2021;9:1133\u201341.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1125_CR74","doi-asserted-by":"publisher","first-page":"L599","DOI":"10.1152\/ajplung.00324.2002","volume":"284","author":"SL Tilley","year":"2003","unstructured":"Tilley SL, et al. Receptors and pathways mediating the effects of prostaglandin E2 on airway tone. Am J Physiol Lung Cell Mol Physiol. 2003;284:L599-606.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"1125_CR75","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1164\/rccm.200903-0388OC","volume":"180","author":"SA Maher","year":"2009","unstructured":"Maher SA, Birrell MA, Belvisi MG. Prostaglandin E2 mediates cough via the EP3 receptor: implications for future disease therapy. Am J Respir Crit Care Med. 2009;180:923\u20138.","journal-title":"Am J Respir Crit Care Med"},{"key":"1125_CR76","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41577-022-00704-5","volume":"22","author":"H Spits","year":"2022","unstructured":"Spits H, Mjosberg J. Heterogeneity of type 2 innate lymphoid cells. Nat Rev Immunol. 2022;22:701\u201312.","journal-title":"Nat Rev Immunol"},{"key":"1125_CR77","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jaci.2016.11.023","volume":"140","author":"JJ Eastman","year":"2017","unstructured":"Eastman JJ, et al. Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2017;140:101-108 e103.","journal-title":"J Allergy Clin Immunol"},{"key":"1125_CR78","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2500\/ajra.2018.32.4498","volume":"32","author":"AA White","year":"2018","unstructured":"White AA, Doherty TA. Role of group 2 innate lymphocytes in aspirin-exacerbated respiratory disease pathogenesis. Am J Rhinol Allergy. 2018;32:7\u201311.","journal-title":"Am J Rhinol Allergy"},{"key":"1125_CR79","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.jaci.2013.09.020","volume":"133","author":"JE Chang","year":"2014","unstructured":"Chang JE, Doherty TA, Baum R, Broide D. Prostaglandin D2 regulates human type 2 innate lymphoid cell chemotaxis. J Allergy Clin Immunol. 2014;133:899-901 e893.","journal-title":"J Allergy Clin Immunol"},{"key":"1125_CR80","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1084\/jem.193.2.255","volume":"193","author":"H Hirai","year":"2001","unstructured":"Hirai H, et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med. 2001;193:255\u201361.","journal-title":"J Exp Med"},{"key":"1125_CR81","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jaci.2013.03.048","volume":"132","author":"TA Doherty","year":"2013","unstructured":"Doherty TA, et al. Lung type 2 innate lymphoid cells express cysteinyl leukotriene receptor 1, which regulates TH2 cytokine production. J Allergy Clin Immunol. 2013;132:205\u201313.","journal-title":"J Allergy Clin Immunol"},{"key":"1125_CR82","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.jaci.2016.12.958","volume":"140","author":"M Salimi","year":"2017","unstructured":"Salimi M, et al. Cysteinyl leukotriene E(4) activates human group 2 innate lymphoid cells and enhances the effect of prostaglandin D(2) and epithelial cytokines. J Allergy Clin Immunol. 2017;140:1090-1100 e1011.","journal-title":"J Allergy Clin Immunol"},{"key":"1125_CR83","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jaci.2020.04.031","volume":"147","author":"WW Stevens","year":"2021","unstructured":"Stevens WW, et al. Activation of the 15-lipoxygenase pathway in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2021;147:600\u201312.","journal-title":"J Allergy Clin Immunol"},{"key":"1125_CR84","doi-asserted-by":"crossref","unstructured":"Nagasaki T,\u00a0et al.\u00a015LO1 dictates glutathione redox changes in asthmatic airway epithelium to worsen type 2 inflammation. J Clin Invest. 2022;132.","DOI":"10.1172\/JCI151685"},{"key":"1125_CR85","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41588-018-0314-6","volume":"51","author":"RP Kristjansson","year":"2019","unstructured":"Kristjansson RP, et al. A loss-of-function variant in ALOX15 protects against nasal polyps and chronic rhinosinusitis. Nat Genet. 2019;51:267\u201376.","journal-title":"Nat Genet"},{"key":"1125_CR86","doi-asserted-by":"publisher","first-page":"AB160","DOI":"10.1016\/j.jaci.2021.12.532","volume":"149","author":"N Chowdhury","year":"2022","unstructured":"Chowdhury N, Chandra R, Li P, Cahill K, Turner J. Aspirin exacerbated respiratory disease can be accurately identified using sinonasal mucus lipid biomarkers. Journal of Allergy and Clinical Immunology. 2022;149:AB160.","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"1125_CR87","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/cea.12797","volume":"47","author":"GY Ban","year":"2017","unstructured":"Ban GY, et al. Metabolomic analysis identifies potential diagnostic biomarkers for aspirin-exacerbated respiratory disease. Clin Exp Allergy. 2017;47:37\u201347.","journal-title":"Clin Exp Allergy"},{"key":"1125_CR88","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.791","volume":"11","author":"A Peric","year":"2023","unstructured":"Peric A, Gacesa D, Cvetkovic G, Vojvodic D. Inflammatory mediators in nasal secretions of patients with nasal polyposis with and without aspirin sensitivity. Immun Inflamm Dis. 2023;11: e791.","journal-title":"Immun Inflamm Dis"},{"key":"1125_CR89","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.exphem.2005.10.012","volume":"34","author":"E Mortaz","year":"2006","unstructured":"Mortaz E, Redegeld FA, Nijkamp FP, Wong HR, Engels F. Acetylsalicylic acid-induced release of HSP70 from mast cells results in cell activation through TLR pathway. Exp Hematol. 2006;34:8\u201318.","journal-title":"Exp Hematol"},{"key":"1125_CR90","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1164\/ajrccm\/143.5_Pt_1.1025","volume":"143","author":"PE Christie","year":"1991","unstructured":"Christie PE, et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis. 1991;143:1025\u20139.","journal-title":"Am Rev Respir Dis"},{"key":"1125_CR91","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.anai.2018.05.007","volume":"121","author":"DM Lang","year":"2018","unstructured":"Lang DM, et al. Omalizumab can inhibit respiratory reaction during aspirin desensitization. Ann Allergy Asthma Immunol. 2018;121:98\u2013104.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1125_CR92","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1164\/rccm.201906-1215OC","volume":"201","author":"H Hayashi","year":"2020","unstructured":"Hayashi H, et al. Omalizumab for aspirin hypersensitivity and leukotriene overproduction in aspirin-exacerbated respiratory disease. A randomized controlled trial. Am J Respir Crit Care Med. 2020;201:1488\u201398.","journal-title":"Am J Respir Crit Care Med"},{"key":"1125_CR93","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jaip.2021.09.050","volume":"10","author":"T Quint","year":"2022","unstructured":"\u2022 Quint T, et al. Omalizumab-induced aspirin tolerance in nonsteroidal anti-inflammatory drug-exacerbated respiratory disease patients is independent of atopic sensitization. J Allergy Clin Immunol Pract. 2022;10:506-516 e506. This article demonstrates the central blocking effect of a mast cell targeted treatment in AERD.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1125_CR94","doi-asserted-by":"publisher","first-page":"254","DOI":"10.4193\/Rhino15.207","volume":"54","author":"L Machado-Carvalho","year":"2016","unstructured":"Machado-Carvalho L, et al. Altered expression and signalling of EP2 receptor in nasal polyps of AERD patients: role in inflammation and remodelling. Rhinology. 2016;54:254\u201365.","journal-title":"Rhinology"},{"key":"1125_CR95","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12931-014-0100-7","volume":"15","author":"L Machado-Carvalho","year":"2014","unstructured":"Machado-Carvalho L, Roca-Ferrer J, Picado C. Prostaglandin E2 receptors in asthma and in chronic rhinosinusitis\/nasal polyps with and without aspirin hypersensitivity. Respir Res. 2014;15:100.","journal-title":"Respir Res"},{"key":"1125_CR96","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/j.jaci.2013.12.1034","volume":"133","author":"TM Laidlaw","year":"2014","unstructured":"Laidlaw TM, et al. Prostaglandin E2 resistance in granulocytes from patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2014;133:1692-1701 e1693.","journal-title":"J Allergy Clin Immunol"},{"key":"1125_CR97","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jaci.2015.09.028","volume":"137","author":"L Machado-Carvalho","year":"2016","unstructured":"Machado-Carvalho L, et al. Low E-prostanoid 2 receptor levels and deficient induction of the IL-1beta\/IL-1 type I receptor\/COX-2 pathway: vicious circle in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016;137:99-107 e107.","journal-title":"J Allergy Clin Immunol"},{"key":"1125_CR98","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1111\/all.14662","volume":"76","author":"K Miyake","year":"2021","unstructured":"Miyake K, Shibata S, Yoshikawa S, Karasuyama H. Basophils and their effector molecules in allergic disorders. Allergy. 2021;76:1693\u2013706.","journal-title":"Allergy"},{"key":"1125_CR99","doi-asserted-by":"publisher","first-page":"101724","DOI":"10.1016\/j.isci.2020.101724","volume":"23","author":"N Vivanco Gonzalez","year":"2020","unstructured":"Vivanco Gonzalez N, et al. Mass cytometry phenotyping of human granulocytes reveals novel basophil functional heterogeneity. iScience. 2020;23:101724.","journal-title":"iScience"},{"key":"1125_CR100","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.jaci.2021.02.045","volume":"148","author":"WW Stevens","year":"2021","unstructured":"\u2022 Stevens WW, et al. Studies of the role of basophils in aspirin-exacerbated respiratory disease pathogenesis. J Allergy Clin Immunol. 2021;148:439-449 e435. This article convincingly demonstrates the importance of the basophil in AERD.","journal-title":"J Allergy Clin Immunol"},{"key":"1125_CR101","doi-asserted-by":"publisher","first-page":"6548","DOI":"10.4049\/jimmunol.154.12.6548","volume":"154","author":"CL Kepley","year":"1995","unstructured":"Kepley CL, Craig SS, Schwartz LB. Identification and partial characterization of a unique marker for human basophils. J Immunol. 1995;154:6548\u201355.","journal-title":"J Immunol"},{"key":"1125_CR102","doi-asserted-by":"crossref","unstructured":"Widal F, Abrami P, Lermoyez J. In Allergy and asthma proceedings. (OceanSide Publications, 1993), vol. 14, pp. 373.","DOI":"10.2500\/108854193778774065"},{"key":"1125_CR103","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/0091-6749(80)90143-8","volume":"66","author":"DD Stevenson","year":"1980","unstructured":"Stevenson DD, Simon RA, Mathison DA. Aspirin-sensitive asthma: tolerance to aspirin after positive oral aspirin challenges. J Allergy Clin Immunol. 1980;66:82\u20138.","journal-title":"J Allergy Clin Immunol"},{"key":"1125_CR104","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1177\/1945892418770260","volume":"32","author":"KM Walters","year":"2018","unstructured":"Walters KM, Waldram JD, Woessner KM, White AA. Long-term clinical outcomes of aspirin desensitization with continuous daily aspirin therapy in aspirin-exacerbated respiratory disease. Am J Rhinol Allergy. 2018;32:280\u20136.","journal-title":"Am J Rhinol Allergy"},{"key":"1125_CR105","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/0091-6749(84)90361-0","volume":"73","author":"DD Stevenson","year":"1984","unstructured":"Stevenson DD, et al. Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of treatment with aspirin. J Allergy Clin Immunol. 1984;73:500\u20137.","journal-title":"J Allergy Clin Immunol"},{"key":"1125_CR106","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1067\/mai.2003.7","volume":"111","author":"MP Berges-Gimeno","year":"2003","unstructured":"Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2003;111:180\u20136.","journal-title":"J Allergy Clin Immunol"},{"key":"1125_CR107","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/alr.22643","volume":"11","author":"AM Sweis","year":"2021","unstructured":"Sweis AM, et al. Major complications of aspirin desensitization and maintenance therapy in aspirin-exacerbated respiratory disease. Int Forum Allergy Rhinol. 2021;11:115\u20139.","journal-title":"Int Forum Allergy Rhinol"},{"key":"1125_CR108","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.jaip.2018.09.012","volume":"7","author":"RC Eid","year":"2019","unstructured":"Eid RC, Palumbo ML, Laidlaw TM, Buchheit KM, Cahill KN. A retrospective analysis of esophageal eosinophilia in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2019;7:1338\u201340.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1125_CR109","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jaci.2021.12.787","volume":"150","author":"KN Cahill","year":"2022","unstructured":"Cahill KN, et al. Mediator production and severity of aspirin-induced respiratory reactions: impact of sampling site and body mass index. J Allergy Clin Immunol. 2022;150:170-177 e176.","journal-title":"J Allergy Clin Immunol"},{"key":"1125_CR110","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jaci.2007.06.047","volume":"121","author":"M Shaker","year":"2008","unstructured":"Shaker M, et al. An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2008;121:81\u20137.","journal-title":"J Allergy Clin Immunol"},{"key":"1125_CR111","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1164\/ajrccm.157.4.9707089","volume":"157","author":"B Dahlen","year":"1998","unstructured":"Dahlen B, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med. 1998;157:1187\u201394.","journal-title":"Am J Respir Crit Care Med"},{"key":"1125_CR112","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.jaip.2015.03.001","volume":"3","author":"V Ta","year":"2015","unstructured":"Ta V, White AA. Survey-defined patient experiences with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2015;3:711\u20138.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1125_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjoto.2021.103227","volume":"43","author":"CA Makary","year":"2022","unstructured":"Makary CA, et al. Long-term role of zileuton in the treatment of chronic rhinosinusitis in aspirin exacerbated respiratory disease. Am J Otolaryngol. 2022;43: 103227.","journal-title":"Am J Otolaryngol"},{"key":"1125_CR114","doi-asserted-by":"publisher","first-page":"3790","DOI":"10.1182\/blood-2011-10-384826","volume":"119","author":"TM Laidlaw","year":"2012","unstructured":"Laidlaw TM, et al. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood. 2012;119:3790\u20138.","journal-title":"Blood"},{"key":"1125_CR115","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jaci.2018.06.001","volume":"143","author":"TM Laidlaw","year":"2019","unstructured":"Laidlaw TM, et al. A trial of type 12 purinergic (P2Y(12)) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2019;143:316-324 e317.","journal-title":"J Allergy Clin Immunol"},{"key":"1125_CR116","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1183\/09031936.00092111","volume":"41","author":"D Singh","year":"2013","unstructured":"Singh D, et al. Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459. Eur Respir J. 2013;41:46\u201352.","journal-title":"Eur Respir J"},{"key":"1125_CR117","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12931-018-0912-y","volume":"19","author":"J Yang","year":"2018","unstructured":"Yang J, et al. Efficacy and safety of antagonists for chemoattractant receptor-homologous molecule expressed on Th2 cells in adult patients with asthma: a meta-analysis and systematic review. Respir Res. 2018;19:217.","journal-title":"Respir Res"},{"key":"1125_CR118","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/cea.14158","volume":"52","author":"CPE Price","year":"2022","unstructured":"Price CPE, et al. Efficacy of an oral CRTH2 antagonist (AZD1981) in the treatment of chronic rhinosinusitis with nasal polyps in adults: a randomized controlled clinical trial. Clin Exp Allergy. 2022;52:859\u201367.","journal-title":"Clin Exp Allergy"},{"key":"1125_CR119","doi-asserted-by":"publisher","first-page":"32109","DOI":"10.1038\/srep32109","volume":"6","author":"K Kobayashi","year":"2016","unstructured":"Kobayashi K, et al. Thromboxane A2 exacerbates acute lung injury via promoting edema formation. Sci Rep. 2016;6:32109.","journal-title":"Sci Rep"},{"key":"1125_CR120","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jaci.2023.03.030","volume":"152","author":"TM Laidlaw","year":"2023","unstructured":"Laidlaw TM, et al. Trial of thromboxane receptor inhibition with ifetroban: TP receptors regulate eicosanoid homeostasis in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2023;152:700-710 e703.","journal-title":"J Allergy Clin Immunol"},{"key":"1125_CR121","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1365-2222.1976.tb01907.x","volume":"6","author":"A Basomba","year":"1976","unstructured":"Basomba A, Romar A, Pelaez A, Villalmanzo IG, Campos A. The effect of sodium cromoglycate in preventing aspirin induced bronchospasm. Clin Allergy. 1976;6:269\u201375.","journal-title":"Clin Allergy"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-024-01125-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11882-024-01125-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-024-01125-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T08:09:07Z","timestamp":1707898147000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11882-024-01125-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,13]]},"references-count":121,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1125"],"URL":"https:\/\/doi.org\/10.1007\/s11882-024-01125-1","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"value":"1529-7322","type":"print"},{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,13]]},"assertion":[{"value":"3 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"E.M.A is co-inventor of patent WO\/2018\/160496 (microglia differentiation and use) and serves as advisory board member and consulting agreements with StemPharm Inc. and Neucyte Inc. and advisory participant for Amgen and AstraZeneca. AAW is on the speaker\u2019s bureau for Astrazeneca\/Amgen, GSK, Optinose, Regeneron\/Sanofi, and Blueprint Pharmaceuticals.  AAW is an advisory board member for Cogent Pharmaceuticals, Blueprint Pharmaceuticals, Regeneron\/Sanofi, AstraZeneca and GSK.  AAW has research support from AstraZeneca and Regeneron.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}},{"value":"This article does not contain any studies with human or animal subjects peformed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}